MétaCan
Menu
Back to cohort
Record W4412491507 · doi:10.1212/wnl.0000000000213905

Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression

2025· article· en· W4412491507 on OpenAlexaff
Marianna Cortese, Xiaojing Peng, Gilles Edan, Mark S. Freedman, Hans‐Peter Hartung, Xavier Montalbán, Rupert Sandbrink, Ernst‐Wilhelm Radü, Frederik Barkhof, Eva‐Maria Wicklein, Ludwig Kappos, Alberto Ascherio, Kjetil Bjørnevik, Siegrid Strasser‐Fuchs, Klaus V. Toyka, Christian Sindic, Bénédicte Dubois, Dominique Dive, Valérie Delvaux, Jan Debruyne, Luanne M. Metz, George P. Rice, Marcelo Kremenchutzky, Pierre Duquette, Yves Lapierre, Mark Freedman, A. John Petkau, Anthony Traboulsee, Paul O’Connor, Petr Štourač, Radomír Taláb, Martin Vališ, Olga Zapletalová, Ivana Kovářová, Eva Medová, Jiří Fiedler, Jette Lautrup Frederiksen, Bruno Brochet, Thibault Moreau, Patrick Vermersch, Jean Pelletier, Gilles Edan, Michel Clanet, David Brassat, Pierre Clavelou, Christine Lebrun‐Frénay, Olivier Gout, Mikko Kallela, Tuula Pirttilä, Juhani Ruutiainen, Juha-Pekka Erälinna, Keijo Koivisto, Mauri Reunanen, Irma Keskinarkaus, Irina Elovaara, Arno Villringer, H. Altenkirch, Lars Bauer, Christoph Pohl, Karl Wessel, Hans-Peter Hartung, Wolfgang Steinke, Bernd C. Kieseier, Hans Wolfgang Kölmel, Patrick Oschmann, Martin Berghoff, Ricarda Diem, Bernd Kitze, Alexander Dressel, Frank Hoffmann, Karl Baum, Stefan Jung, Hela-Felicitas Petereit, D. Reske, Michael Sailer, Jürgen Köhler, Björn Tackenberg, Luisa Klotz, Reinhard Hohlfeld, Tania Kuempfel, Karl‐Heinz Henn, Andreas Steinbrecher, Klemens Angstwurm, Hayrettin Tumani, Ralf Gold, Christoph Kleinschnitz, Sámuel Komoly, Gyula Gács, Gábor Jakab, Gyula Pánczél, Tünde Csépány, László Csiba, László Vécsei, Ariel Miller, Dimitrios Karussis, Joab Chapman, Angelo Ghezzi, Gıancarlo Comı, Vittorio Martinelli, Paolo Gallo, Vittorio Cosi, Roberto Bergamaschi, Luca Durelli, Paola Cavalla, Kjell‐Morten Myhr, Andrzej Szczudlik, Krzysztof Selmaj, Z Stelmasiak, Halina BarosikPsujek, Ryszard Podemski, Zdzisław Maciejek, Sławomir Wawrzyniak, Luı́s Cunha, Saša Šega‐Jazbec, T. Arbizu, Albert Saiz Hinarejos, Joseba Bárcena, Sergio Martínez‐Yélamos, Rafael Arroyo, Óscar Fernández Fernández, Guillermo Izquierdo‐Ayuso, Bonaventura Casanova i Estruch, Jan Lycke, Sophie Wu, Jens Kühle, W. Radue, Heinrich P. Mattle, Karsten Beer, Jürg Kesselring, Chris H. Polman, Bernard M.J. Uitdehaag, Bert Anten, Raymond Hupperts, Leo H. Visser, Richard A. Coleman, Jeremy Chataway, David H. Miller, J O’Riordan, Stephen Howell, Henry F. McFarlan

Bibliographic record

VenueNeurology · 2025
Typearticle
Languageen
FieldMedicine
TopicMultiple Sclerosis Research Studies
Canadian institutionsOttawa HospitalUniversity of Ottawa
Fundersnot available
KeywordsMedicineQuartilealpha-Linolenic acidInternal medicinePolyunsaturated fatty acidProspective cohort studyHazard ratioLower riskProportional hazards modelFatty acidGastroenterologyCohortConfidence intervalDocosahexaenoic acidBiologyBiochemistry

Abstract

fetched live from OpenAlex

BACKGROUND AND OBJECTIVES: Higher dietary intake of alpha-linolenic acid (ALA), a plant-derived omega-3 polyunsaturated fatty acid (PUFA), was associated with a lower risk of multiple sclerosis (MS) in a prospective cohort study and lower risk of new lesions, relapses, and disability progression in a patient cohort. We examined whether serum levels of ALA and other PUFAs predicted MS outcomes up to 11 years after clinical onset. METHODS: This prospective study was conducted among participants in the BENEFIT clinical trial, who had serum samples collected starting at randomization. Serum fatty acids were measured using gas chromatography. We evaluated the association of individual fatty acids with time to clinically definite MS (CDMS) and other measures of disease activity and progression using Cox, negative binomial, and linear regression. RESULTS: We followed 468 participants for 5 years, including 278 followed to year 11. At baseline, the median age was 30 years and 71% were women. Higher baseline serum ALA levels were associated with a lower risk of CDMS and relapses during follow-up. The multivariable-adjusted hazard ratios for CDMS comparing top to bottom quartile were 0.60 (95% CI 0.39-0.95) and 0.60 (95% CI 0.37-0.98) after 5 and 11 years, respectively. The multivariable adjusted risk ratios for relapses comparing top to bottom quartile were 0.60 (95% CI 0.38-0.94) and 0.65 (95% CI 0.43-0.99) after 5 and 11 years, respectively. None of the other 35 fatty acids were associated with CDMS risk. Three fatty acids were associated with relapse rate after 5 years, but not 11 years. Higher ALA levels were associated with a slower decline in MS Functional Composite, an assessment of disability, at 5 years. The association was similar at 11 years, but the results did not retain statistical significance. Baseline ALA levels were not associated with subsequent changes in cognitive function, time to confirmed Expanded Disability Status Scale progression, new active lesions, or brain volume loss. DISCUSSSION: Higher serum ALA levels were associated with a lower risk of CDMS, relapses, and disability progression in a large prospective cohort. The results were null or inconsistent for other fatty acids.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.055
GPT teacher head0.339
Teacher spread0.284 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueNeurologySame topicMultiple Sclerosis Research StudiesFrench-language works237,207